James Lovgren is the CEO and Co-founder of Aspiro Therapeutics, a preclinical-stage company developing a novel inhaled peptide therapeutic for obstructive lung diseases. The company’s lead program focuses on a CC16-derived peptidomimetic designed to address underlying disease biology in asthma and COPD through targeted pulmonary delivery.

James is an accomplished life sciences executive with over 20 years of experience commercializing innovative technologies and supporting drug development programs. His background includes leadership roles at Thermo Fisher Scientific and MaxCyte, where he led global product strategy and supported the growth of advanced cell therapy and life science platforms.

He holds a BS in Biology from the University of North Florida and an MBA from North Carolina State University.